Comparison 2. Mannitol versus control ‐ cross‐over studies of individuals with cystic fibrosis.

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
2.1 FEV1 % predicted (absolute change from baseline)	1	174	Mean Difference (IV, Fixed, 95% CI)	3.42 [1.13, 5.71]
2.2 FEV1 % predicted (absolute change from baseline ‐ subgroup analysis by age)	1		Mean Difference (IV, Fixed, 95% CI)	Subtotals only
2.2.1 age 6 to 11 years	1	78	Mean Difference (IV, Fixed, 95% CI)	3.78 [0.13, 7.43]
2.2.2 age 12 to 17 years	1	106	Mean Difference (IV, Fixed, 95% CI)	3.35 [0.14, 6.56]
2.3 FEV1 % predicted (absolute change from baseline ‐ subgroup analysis by dornase alfa use	1		Mean Difference (IV, Fixed, 95% CI)	Subtotals only
2.3.1 Dornase alfa user	1	126	Mean Difference (IV, Fixed, 95% CI)	3.29 [0.28, 6.30]
2.3.2 Dornase alfa non‐user	1	58	Mean Difference (IV, Fixed, 95% CI)	3.92 [0.42, 7.42]
2.4 FEV1 % predicted (relative change from baseline)	1	174	Mean Difference (IV, Fixed, 95% CI)	4.97 [1.52, 8.42]
2.5 FVC % predicted (absolute change from baseline)	1	174	Mean Difference (IV, Fixed, 95% CI)	1.80 [‐0.72, 4.32]
2.6 FVC % predicted (relative change from baseline)	1	174	Mean Difference (IV, Fixed, 95% CI)	2.54 [‐0.72, 5.80]
2.7 FEF25-75 % predicted (absolute change from baseline)	1	174	Mean Difference (IV, Fixed, 95% CI)	5.75 [1.81, 9.69]
2.8 FEF25-75 % predicted (relative change from baseline)	1	174	Mean Difference (IV, Fixed, 95% CI)	10.52 [2.31, 18.73]
2.9 Sputum weight (grams) (post‐initial treatment)	1	174	Mean Difference (IV, Fixed, 95% CI)	1.33 [0.29, 2.37]